Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

被引：0

作者：

Kim, H. ^{[1
]}

Park, S. ^{[2
]}

Kim, T. M. ^{[3
]}

Han, J-Y. ^{[4
]}

Lee, G-W. ^{[5
,6
]}

Shim, B. Y. ^{[7
]}

Lee, Y-G. ^{[8
]}

Kim, S-W. ^{[9
]}

Ock, C-Y. ^{[10
]}

Hwang, S. ^{[11
]}

Lee, Y. ^{[12
]}

Kim, R. ^{[13
]}

Jung, H. A. ^{[14
]}

Sun, J-M. ^{[15
]}

Lee, S-H. ^{[16
]}

Ahn, J. S. ^{[15
]}

Ahn, M-J. ^{[17
]}

机构：

[1] Samsung Med Ctr SMC, Hematooncol, Seoul, South Korea

[2] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea

[3] Seoul Natl Univ, Internal Med Dept, Coll Med, Yeongeon Med Campus, Seoul, South Korea

[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Ctr Lung Canc, Goyang, South Korea

[5] Gyeongsang Natl Univ Hosp, Internal Med Dept, Jinju, South Korea

[6] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea

[7] Catholic Univ Korea, Dept Internal Med, St Vincents Hosp, Suwon, South Korea

[8] Kangbuk Samsung Hosp, Samsung Med Ctr SMC, Dept Internal Med, Seoul, South Korea

[9] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[10] Lunit Inc, Med Affairs, Oncol Grp, Seoul, South Korea

[11] Lunit, Med Affairs, Oncol Grp, Seoul, South Korea

[12] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea

[13] Inocras, Oncol Dept, San Diego, CA USA

[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Hematol Oncol,Dept Med, Seoul, South Korea

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea

[16] Samsung Med Ctr SMC, Med Oncol, Seoul, South Korea

[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Hematol Oncol Dept, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

631P

引用

页码：S1636 / S1636

页数：1

共 50 条

[1] NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
Trummer, Arne
Bethge, Andre
Dickgreber, Nicolas
Dittrich, Ina
Golpon, Heiko
Hoffknecht, Petra
Overbeck, Tobias R.
Wesseler, Claas
Reck, Martin
LUNG CANCER, 2022, 174 : 141 - 145
[2] Phase II Trial of Pemetrexed/Carboplatin/Bevacizumab plus /- Atezolizumab in NSCLC Patients That Are EGFR Mutated or Never Smoked
Bodor, J. N.
Patel, J.
Ross, E.
Litwin, S.
Treat, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S404 - S404
[3] NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
Trummer, Arne Rainer
Bethge, Andre
Dickgreber, Nicolas J.
Dittrich, Ina
Golpon, Heiko
Hoffknecht, Petra
Overbeck, Tobias R.
Wesseler, Claas
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
Ahn, M. J.
Park, S.
Kim, T. M.
Han, J. Y.
Lee, G. W.
Shim, B.
Lee, Y. G.
Kim, S. W.
Kim, I. H.
Lee, S.
Kim, Y. J.
Park, J. H.
Park, S. G.
Lee, K. H.
Kang, E. J.
Kim, J. W.
Shin, S. H.
ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1311
[5] Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
Park, Sehhoon
Kim, Tae Min
Han, Ji-Youn
Lee, Gyeong-Won
Shim, Byoung Yong
Lee, Yun-Gyoo
Kim, Sang-We
Kim, Il Hwan
Lee, Suee
Kim, Yu Jung
Park, Ji Hyun
Park, Sang-Gon
Lee, Ki Hyeong
Kang, Eun Joo
Kim, Ju Won
Shin, Seong-Hoon
Ock, Chan-Young
Nam, Byung-Ho
Lee, Jaebong
Jung, Hyun-Ae
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1241 - 1251
[6] Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC.
Yeh, Tammie C.
Angell, Helen K.
Rowlands, Vicky
Jones, Emma V.
Ros, Vidalba Rocher
Pritchard, Alison
Roudier, Martine P.
Standifer, Nathan
Kuziora, Mike
Martin, Philip
Peskov, Kirill
Taylor, Rosie
Barrett, J. Carl
Sidders, Ben
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 112 - 113
[7] Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study
Pasello, G.
Lorenzi, M.
Crivellaro, G.
Capelletto, E.
Buttice, S.
Perrone, F.
Tiseo, M.
Scotti, V.
Polo, V.
Favaretto, A.
Montrone, M.
Berardi, R.
Zustovich, F.
Toschi, L.
Bearz, A.
Milella, M.
Frega, S.
Bonanno, L.
Guarneri, V.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S52 - S53
[8] A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Lam, T. C.
Tsang, K.
Choi, H.
Lee, V. H. F.
Lam, K. O.
Chiang, C. L.
So, T. H.
Chan, W. W.
Nyaw, S. F.
Lim, F.
Lau, J. O.
Chik, J.
Kong, S. F.
Lee, A. W. M.
ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1389
[9] IMpower151: Phase III Study of Atezolizumab plus Bevacizumab plus Chemotherapy in 1L Metastatic Nonsquamous NSCLC
Zhou, C.
Dong, X.
Chen, G.
Wang, Z.
Wu, X.
Yao, Y.
Zhang, Y.
Cheng, Y.
Pan, H.
Zhang, X.
Cui, J.
Wang, L.
Chen, X.
Li, X.
Wang, Z.
Wang, Q.
He, J.
Wang, M.
Yan, I.
Qian, L.
An, A.
Cai, A.
Wu, Q.
Ballinger, M.
Wang, L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S64 - S65
[10] Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) (vol 42, 10.1200/JCO.23.01891, 2023)
Park, Sehhoon
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22) : 2725 - 2725

← 1 2 3 4 5 →